These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus. Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834 [TBL] [Abstract][Full Text] [Related]
5. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase. Mina-Osorio P; LaStant J; Keirstead N; Whittard T; Ayala J; Stefanova S; Garrido R; Dimaano N; Hilton H; Giron M; Lau KY; Hang J; Postelnek J; Kim Y; Min S; Patel A; Woods J; Ramanujam M; DeMartino J; Narula S; Xu D Arthritis Rheum; 2013 Sep; 65(9):2380-91. PubMed ID: 23754328 [TBL] [Abstract][Full Text] [Related]
6. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice. Sitrin J; Suto E; Wuster A; Eastham-Anderson J; Kim JM; Austin CD; Lee WP; Behrens TW J Immunol; 2017 Aug; 199(4):1238-1249. PubMed ID: 28696253 [TBL] [Abstract][Full Text] [Related]
7. BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis. Chalmers SA; Garcia SJ; Webb D; Herlitz L; Fine J; Klein E; Ramanujam M; Putterman C Clin Immunol; 2021 Feb; 223():108640. PubMed ID: 33296718 [TBL] [Abstract][Full Text] [Related]
8. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Kim YY; Park KT; Jang SY; Lee KH; Byun JY; Suh KH; Lee YM; Kim YH; Hwang KW Arthritis Res Ther; 2017 Sep; 19(1):211. PubMed ID: 28950886 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis. Kong W; Deng W; Sun Y; Huang S; Zhang Z; Shi B; Chen W; Tang X; Yao G; Feng X; Sun L Clin Rheumatol; 2018 Jan; 37(1):43-49. PubMed ID: 28612243 [TBL] [Abstract][Full Text] [Related]
10. CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice. Bignon A; Gaudin F; Hémon P; Tharinger H; Mayol K; Walzer T; Loetscher P; Peuchmaur M; Berrebi D; Balabanian K J Immunol; 2014 Feb; 192(3):886-96. PubMed ID: 24367031 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116 [TBL] [Abstract][Full Text] [Related]
13. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Lourenço EV; Wong M; Hahn BH; Palma-Diaz MF; Skaggs BJ Arthritis Rheumatol; 2014 Mar; 66(3):674-85. PubMed ID: 24574228 [TBL] [Abstract][Full Text] [Related]
14. B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. Jacob N; Guo S; Mathian A; Koss MN; Gindea S; Putterman C; Jacob CO; Stohl W J Immunol; 2011 Apr; 186(8):4984-93. PubMed ID: 21383240 [TBL] [Abstract][Full Text] [Related]
15. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis. Liao W; Zheng H; Wu S; Zhang Y; Wang W; Zhang Z; Zhou C; Wu H; Min J Am J Nephrol; 2017; 46(5):371-379. PubMed ID: 29069649 [TBL] [Abstract][Full Text] [Related]
16. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Hutcheson J; Vanarsa K; Bashmakov A; Grewal S; Sajitharan D; Chang BY; Buggy JJ; Zhou XJ; Du Y; Satterthwaite AB; Mohan C Arthritis Res Ther; 2012 Nov; 14(6):R243. PubMed ID: 23136880 [TBL] [Abstract][Full Text] [Related]
17. Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis. Cheng Q; Mumtaz IM; Khodadadi L; Radbruch A; Hoyer BF; Hiepe F Ann Rheum Dis; 2013 Dec; 72(12):2011-7. PubMed ID: 24114925 [TBL] [Abstract][Full Text] [Related]
18. Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis. Kanapathippillai P; Hedberg A; Fenton CG; Fenton KA Cytokine; 2013 May; 62(2):244-52. PubMed ID: 23561928 [TBL] [Abstract][Full Text] [Related]
19. Antroquinonol differentially modulates T cell activity and reduces interleukin-18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis. Tsai PY; Ka SM; Chang JM; Lai JH; Dai MS; Jheng HL; Kuo MT; Chen P; Chen A Arthritis Rheum; 2012 Jan; 64(1):232-42. PubMed ID: 21905011 [TBL] [Abstract][Full Text] [Related]
20. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Lin W; Seshasayee D; Lee WP; Caplazi P; McVay S; Suto E; Nguyen A; Lin Z; Sun Y; DeForge L; Balazs M; Martin F; Zarrin AA Arthritis Rheumatol; 2015 Jan; 67(1):215-24. PubMed ID: 25303150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]